Point72 Hong Kong Ltd Has $36,000 Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

More from Author Samuel Edwards here: https://globelivemedia.com/author/samuel-edwards/

Point72 Hong Kong Ltd lowered its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 71.1% in the third quarter, HoldingsChannel reports. The institutional investor owned 502 shares of the company’s stock after selling 1,236 shares during the period. Point72 Hong Kong Ltd’s holdings in Axsome Therapeutics were worth $36,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. UBS Asset Management Americas Inc. lifted its stake in shares of Axsome Therapeutics by 2.0% in the 3rd quarter. UBS Asset Management Americas Inc. now owns 27,673 shares of the company’s stock valued at $1,972,000 after purchasing an additional 545 shares during the last quarter. Great West Life Assurance Co. Can lifted its stake in shares of Axsome Therapeutics by 70.3% in the 3rd quarter. Great West Life Assurance Co. Can now owns 3,500 shares of the company’s stock valued at $42,000 after purchasing an additional 1,445 shares during the last quarter. Pathstone Family Office LLC lifted its stake in shares of Axsome Therapeutics by 279.1% in the 3rd quarter. Pathstone Family Office LLC now owns 1,630 shares of the company’s stock valued at $116,000 after purchasing an additional 1,200 shares during the last quarter. Clearstead Advisors LLC acquired a new stake in shares of Axsome Therapeutics in the 3rd quarter valued at $71,000. Finally, JPMorgan Chase & Co. lifted its stake in shares of Axsome Therapeutics by 10.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 10,414 shares of the company’s stock valued at $753,000 after purchasing an additional 950 shares during the last quarter. 63.63% of the stock is owned by institutional investors.

Several research analysts recently commented on the stock. BidaskClub upgraded shares of Axsome Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday. Bank of America assumed coverage on shares of Axsome Therapeutics in a report on Tuesday, September 29th. They issued an “underperform” rating and a $66.00 target price on the stock. Morgan Stanley dropped their target price on shares of Axsome Therapeutics from $102.00 to $101.00 and set an “overweight” rating on the stock in a report on Monday, November 9th. Cantor Fitzgerald lifted their target price on shares of Axsome Therapeutics from $131.00 to $161.00 and gave the stock an “overweight” rating in a report on Thursday, December 3rd. Finally, William Blair reiterated a “buy” rating on shares of Axsome Therapeutics in a report on Thursday, October 1st. One research analyst has rated the stock with a sell rating and thirteen have given a buy rating to the company’s stock. Axsome Therapeutics has an average rating of “Buy” and an average price target of $137.91.

NASDAQ AXSM opened at $76.91 on Friday. The stock has a market cap of $2.87 billion, a P/E ratio of -28.59 and a beta of 2.58. The company’s 50-day simple moving average is $73.79 and its 200 day simple moving average is $75.94. Axsome Therapeutics, Inc. has a twelve month low of $35.44 and a twelve month high of $109.94. The company has a quick ratio of 9.99, a current ratio of 9.99 and a debt-to-equity ratio of 0.36.

Axsome Therapeutics (NASDAQ:AXSM) last posted its earnings results on Tuesday, November 10th. The company reported ($0.58) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.57) by ($0.01). Research analysts anticipate that Axsome Therapeutics, Inc. will post -2.65 earnings per share for the current year.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the phase III clinical trial for the treatment resistant depression and depressive disorders; and phase II/III clinical trials in agitation associated with Alzheimer’s disease, as well as completed phase II clinical trial for the treatment of smoking cessation.

Institutional Ownership by Quarter for Axsome Therapeutics (NASDAQ:AXSM)

Samuel Edwards
Samuel Edwards is the name you must have heard many times while reading reports related to Finance, that's what he is good at. From Major Investments to Stock Market Updates, he got 'em all. Be ready to blow your mind by the mind-blowing reports of Finance World from Samuel Edwards.